Candel Therapeutics, Inc.
NASDAQ:CADLBiotechnology
+$0.05 today
- Market cap
- $417.33M
- Beta
- -0.48
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$0.87
Volume 1.39M
Average 1.82M
CADL Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Candel Therapeutics, Inc.NASDAQ: CADL
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$8.86M, compared with $7.38M a year earlier. Trailing-twelve-month net income was -$54.42M. Over 3 fiscal years it compounded at +26.7% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 8 analysts of -$65.25M (+70.9%) for the fiscal year ending Dec 2026, a step up from the -30.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.86M-70.0% QoQ
- Last fiscal yearDec 2025
- -$38.18M-30.8% YoY
- LTMMar 2026
- -$54.42M+37.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -220.1% | +267.8% | +487.8 pp |
| 1 year | -30.8% | +70.9% | +101.7 pp |
| 3-year CAGR | +26.7% | +20.2% | -6.4 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (38.18M) USD
- Year-over-year change
- +30.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (38.18M) | +30.8% |
| FY2024 | 2024-12-31 | (55.18M) | -45.4% |
| FY2023 | 2023-12-31 | (37.94M) | -101.9% |
| FY2022 | 2022-12-31 | (18.79M) | +48.0% |
| FY2021 | 2021-12-31 | (36.12M) | — |
Net Income vs competitors
How CADL compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +37.5% is the 3rd highest of 10, against a peer median of +1.8%.
- Over three fiscal years its annual growth of +26.7% compares with a peer median of +13.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $243.25M USD | -26.6% | +24.1% | 112.0% | |
| LTM Sep 2026 | $220.54M USD | -44.5% | -0.4% | 58.2% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥150.96M CNY | -47.8% | -67.2% | — |
| LTM Mar 2026 | $135.21M USD | +1.8% | +13.3% | — | |
| LTM Mar 2026 | $107.79M USD | +391.1% | -58.2% | — | |
| LTM Mar 2026 | $70.36M USD | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $54.42M USD | +37.5% | +26.7% | — | |
| LTM Mar 2026 | $34.98M USD | +67.3% | +52.9% | — | |
GNLXGenelux Corporation | LTM Mar 2026 | $33.58M USD | +13.8% | +83.4% | 419762.5% |
| LTM Mar 2026 | $24.38M USD | -35.9% | +2396.3% | 10.7% | |
| Peer median (excluding CADL) | — | +1.8% | +13.3% | 58.2% | |
Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (36.12M) | (18.79M) | (37.94M) | (55.18M) | (38.18M) |
| Depreciation & Amortization | 232K | 778K | 1.28M | 990K | 845K |
| Deferred Income Tax | 11.51M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.96M | 2.31M | 3.09M | 5.31M | 3.82M |
| Change in Working Capital | (876K) | 71K | (378K) | 346K | 2.19M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 669K | (1.21M) | 45K | (185K) | 802K |
| Other Working Capital | (1.55M) | 1.28M | (378K) | 531K | 1.39M |
| Other Non-Cash Items | 76K | (15.78M) | (301K) | 21.51M | (6.98M) |
| Operating Cash Flow | (22.22M) | (31.42M) | (34.24M) | (27.02M) | (38.31M) |
| Capital Expenditures | (1.84M) | (1.3M) | (457K) | (16K) | (587K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 27K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 177K | 0 | 0 |
| Investing Cash Flow | (1.84M) | (1.3M) | (280K) | (16K) | (560K) |
| Debt Repayment | 0 | 19.91M | 0 | (9.17M) | 36.21M |
| Common Stock Issued | 71.34M | 0 | 0 | 101.76M | 19.89M |
| Common Stock Repurchased | 0 | 0 | (121K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 465K | 64K | 0 | 1.69M | 0 |
| Financing Cash Flow | 71.8M | 19.97M | (121K) | 94.28M | 56.1M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 47.75M | (12.74M) | (34.65M) | 67.24M | 17.23M |
| Free Cash Flow | (24.05M) | (32.72M) | (34.7M) | (27.04M) | (38.9M) |
Candel Therapeutics, Inc.
NASDAQ:CADL
Intrinsic Alpha fair value
Locked
Current Price
$5.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.